MedTrace Logo

Integrating Pharmacogenomic Testing Into a Child Psychiatry Clinic

NCT02855580 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 71

Last updated 2019-06-10

No results posted yet for this study

Summary

The purpose of this study is to examine the feasibility, acceptability, and utility of pharmacogenomic (PGX) testing (specifically for the cytochrome P450 2D6 and 2C19 genes) prior to initiating treatment with an antidepressant (AD) among children and adolescents in the University of Florida Child Psychiatry clinics.

Conditions

Sponsors & Collaborators

  • University of Florida

    lead OTHER

Principal Investigators

  • Carol A Mathews, MD · University of Florida

Eligibility

Min Age
8 Years
Max Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-07-06
Completion
2017-07-06

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02855580 on ClinicalTrials.gov